{"transactions":[{"id":3013420,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-09-28","kind":"sale","acquired":false,"shares":273584,"price":7.5365,"value":2061865.816,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.40 to $7.75 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2381436,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013419,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-09-25","kind":"sale","acquired":false,"shares":174219,"price":7.077,"value":1232947.863,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.00 to $8.15 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2655020,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013418,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-09-24","kind":"sale","acquired":false,"shares":38514,"price":7.629,"value":293823.306,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $7.35 to $7.70 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2829239,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013417,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-08-13","kind":"sale","acquired":false,"shares":159,"price":8.75,"value":1391.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2867753,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013416,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-08-12","kind":"sale","acquired":false,"shares":1335,"price":8.79,"value":11734.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.91 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2867912,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013415,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-07-29","kind":"sale","acquired":false,"shares":2709,"price":8.781,"value":23787.729,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2869247,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013414,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-07-22","kind":"sale","acquired":false,"shares":22651,"price":9.004,"value":203949.604,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.05 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2871956,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013413,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-07-20","kind":"sale","acquired":false,"shares":36983,"price":9.249,"value":342055.767,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.84 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2894607,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013412,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-07-17","kind":"sale","acquired":false,"shares":31101,"price":9.24,"value":287373.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $9.10 to $9.415 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2931590,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3013411,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-10-05T17:00:10.000Z","date":"2020-07-16","kind":"sale","acquired":false,"shares":16332,"price":8.559,"value":139785.588,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $8.50 to $8.685 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. At the time of each reported transaction, the Reporting Person(s) owned greater than 10.0% of LogicBio Therapeutics, Inc.'s (the \"Issuer\") issued and outstanding common stock; however at the time of the filing of this Form 4 the Reporting Person(s) no longer hold 10.0% or more of the Issuer's issued and outstanding common stock."}],"balance_after":2962691,"source":{"system":"sec-edgar","filing":"0000899243-20-027297","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320027297/doc4.xml","form_type":"4"}},{"id":3130731,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-05-29T16:32:05.000Z","date":"2020-05-28","kind":"sale","acquired":false,"shares":366591,"price":21.3342,"value":7820925.7122,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2193704,"source":{"system":"sec-edgar","filing":"0000899243-20-014559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320014559/doc4.xml","form_type":"4"}},{"id":3130730,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2020-05-29T16:32:05.000Z","date":"2020-05-27","kind":"sale","acquired":false,"shares":12064,"price":22.3926,"value":270144.3264,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $22.00 to $24.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2560295,"source":{"system":"sec-edgar","filing":"0000899243-20-014559","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320014559/doc4.xml","form_type":"4"}},{"id":3208992,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-16T17:04:28.000Z","date":"2020-03-16","kind":"exercise","acquired":false,"shares":8611110,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entities affiliated with Arix Bioscience plc"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1367058},"source":{"system":"sec-edgar","filing":"0000899243-20-008474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320008474/doc4.xml","form_type":"4"}},{"id":3208991,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T17:04:28.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":187500,"price":16,"value":3000000.0,"ownership":{"direct":false,"nature":"By entities affiliated with Arix Bioscience plc"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":1554558,"source":{"system":"sec-edgar","filing":"0000899243-20-008474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320008474/doc4.xml","form_type":"4"}},{"id":3208990,"issuer":{"id":4024,"kind":"organization","name":"Enliven Therapeutics, Inc.","symbol":"ELVN"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-16T17:04:28.000Z","date":"2020-03-16","kind":"exercise","acquired":true,"shares":1367058,"ownership":{"direct":false,"nature":"By entities affiliated with Arix Bioscience plc"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":1367058,"source":{"system":"sec-edgar","filing":"0000899243-20-008474","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924320008474/doc4.xml","form_type":"4"}},{"id":3339154,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-17T19:20:01.000Z","date":"2019-12-17","kind":"sale","acquired":false,"shares":12476,"price":16.8298,"value":209968.5848,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $16.80 to $17.00 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2572359,"source":{"system":"sec-edgar","filing":"0000899243-19-029473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319029473/doc4.xml","form_type":"4"}},{"id":3339153,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-17T19:20:01.000Z","date":"2019-12-16","kind":"sale","acquired":false,"shares":13080,"price":17.0245,"value":222680.46,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.28 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the SEC, the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2584835,"source":{"system":"sec-edgar","filing":"0000899243-19-029473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319029473/doc4.xml","form_type":"4"}},{"id":3339152,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-17T19:20:01.000Z","date":"2019-12-13","kind":"sale","acquired":false,"shares":11002,"price":17.2097,"value":189341.1194,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.68 per share, inclusive. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission (the \"SEC\"), the Issuer, or a security holder of the Issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2597915,"source":{"system":"sec-edgar","filing":"0000899243-19-029473","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319029473/doc4.xml","form_type":"4"}},{"id":3346668,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-10T19:27:22.000Z","date":"2019-12-10","kind":"sale","acquired":false,"shares":131696,"price":16.9103,"value":2227018.8688,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2608917,"source":{"system":"sec-edgar","filing":"0000899243-19-028848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319028848/doc4.xml","form_type":"4"}},{"id":3346667,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-10T19:27:22.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":77316,"price":18.1161,"value":1400664.3876,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2740613,"source":{"system":"sec-edgar","filing":"0000899243-19-028848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319028848/doc4.xml","form_type":"4"}},{"id":3346666,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-10T19:27:22.000Z","date":"2019-12-09","kind":"sale","acquired":false,"shares":26438,"price":18.2987,"value":483781.0306,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2817929,"source":{"system":"sec-edgar","filing":"0000899243-19-028848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319028848/doc4.xml","form_type":"4"}},{"id":3346665,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-12-10T19:27:22.000Z","date":"2019-12-06","kind":"sale","acquired":false,"shares":47752,"price":19.1452,"value":914221.5904,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2844367,"source":{"system":"sec-edgar","filing":"0000899243-19-028848","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319028848/doc4.xml","form_type":"4"}},{"id":3656852,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2019-02-14T18:01:24.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":742850,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":742850},"source":{"system":"sec-edgar","filing":"0000899243-19-003683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319003683/doc4.xml","form_type":"4"}},{"id":3656851,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2019-02-14T18:01:24.000Z","date":"2019-02-12","kind":"exercise","acquired":false,"shares":1720698,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1720698},"source":{"system":"sec-edgar","filing":"0000899243-19-003683","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319003683/doc4.xml","form_type":"4"}},{"id":3656850,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-02-14T18:01:24.000Z","date":"2019-02-12","kind":"purchase","acquired":true,"shares":428571,"price":14,"value":5999994.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2892119,"source":{"system":"sec-edgar","filing":"0000899243-19-003683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319003683/doc4.xml","form_type":"4"}},{"id":3656849,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2019-02-14T18:01:24.000Z","date":"2019-02-12","kind":"exercise","acquired":true,"shares":2463548,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Convertible Preferred Stock and the Series C Convertible Preferred Stock converted into Harpoon Therapeutics, Inc. (the \"Issuer\") common stock, on a one-for-one basis, effective upon closing of the Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2463548,"source":{"system":"sec-edgar","filing":"0000899243-19-003683","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924319003683/doc4.xml","form_type":"4"}},{"id":3782332,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-26T09:29:34.000Z","date":"2018-10-23","kind":"exercise","acquired":false,"shares":4352775,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the \"Issuer\") common stock effective upon closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the \"Issuer\") common stock effective upon closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the \"Issuer\") common stock effective upon closing of the Issuer's initial public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2279023},"source":{"system":"sec-edgar","filing":"0000899243-18-027509","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924318027509/doc4.xml","form_type":"4"}},{"id":3782331,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2018-10-26T09:29:34.000Z","date":"2018-10-23","kind":"purchase","acquired":true,"shares":700000,"price":10,"value":7000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2979023,"source":{"system":"sec-edgar","filing":"0000899243-18-027509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924318027509/doc4.xml","form_type":"4"}},{"id":3782330,"issuer":{"id":122292,"kind":"organization","name":"LogicBio Therapeutics, Inc.","symbol":"LOGC"},"owners":[{"id":146164,"kind":"organization","name":"Arix Bioscience plc","position":1,"cik":"0001700449","reported_name":"Arix Bioscience plc","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":146165,"kind":"organization","name":"Arix Bioscience Holdings Ltd","position":2,"cik":"0001756884","reported_name":"Arix Bioscience Holdings Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common stock","published_at":"2018-10-26T09:29:34.000Z","date":"2018-10-23","kind":"exercise","acquired":true,"shares":2279023,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series B Preferred Stock converted into LogicBio Therapeutics, Inc. (the \"Issuer\") common stock effective upon closing of the Issuer's initial public offering."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are owned directly by Arix Bioscience Holdings Limited, which is a wholly owned subsidiary of Arix Bioscience Plc. Arix Bioscience Plc is an indirect beneficial owner of the reported securities and disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein."}],"balance_after":2279023,"source":{"system":"sec-edgar","filing":"0000899243-18-027509","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700449/000089924318027509/doc4.xml","form_type":"4"}}]}